In their quest to understand how cancers take root, grow and spread, scientists have for the past half-century explored the ...

Deep within the cellular landscape, a quiet failure was taking place, impeding a potentially successful form of cancer ...

REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences: Baird 2026 ...

CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 ...

CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy ...

Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September - - Announced new data showing ...

Chronic respiratory diseases substantially magnify pneumococcal pneumonia and invasive disease risk, with especially high CAP ...

Gynecological tumors, including cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC), represent a significant global health burden ...

August has been a game-changing month for BioLineRx, the Israeli biopharmaceutical company that has been making waves in the ...

With $13.1 million on its balance sheet as of June 30, 2026, BioLineRx is maintaining its cash runway guidance into the first half of 2027. On August 27, 2026, the Company entered into a definitive ...